Intellia Therapeutics (NTLA) Equity Average (2016 - 2025)
Historic Equity Average for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to $731.8 million.
- Intellia Therapeutics' Equity Average fell 2430.6% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.8 million, marking a year-over-year decrease of 2430.6%. This contributed to the annual value of $961.1 million for FY2024, which is 1590.85% down from last year.
- According to the latest figures from Q3 2025, Intellia Therapeutics' Equity Average is $731.8 million, which was down 2430.6% from $747.6 million recorded in Q2 2025.
- Over the past 5 years, Intellia Therapeutics' Equity Average peaked at $1.2 billion during Q1 2023, and registered a low of $520.3 million during Q2 2021.
- In the last 5 years, Intellia Therapeutics' Equity Average had a median value of $966.8 million in 2024 and averaged $917.9 million.
- As far as peak fluctuations go, Intellia Therapeutics' Equity Average soared by 15065.51% in 2021, and later crashed by 2550.94% in 2025.
- Over the past 5 years, Intellia Therapeutics' Equity Average (Quarter) stood at $1.1 billion in 2021, then decreased by 4.04% to $1.0 billion in 2022, then rose by 1.31% to $1.0 billion in 2023, then decreased by 12.12% to $917.3 million in 2024, then dropped by 20.22% to $731.8 million in 2025.
- Its Equity Average stands at $731.8 million for Q3 2025, versus $747.6 million for Q2 2025 and $825.9 million for Q1 2025.